Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (280)	10/15/2001 6:46:03 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

Class statement re. third quarter and any increase in business which may or may not develop as a result of post-WTC, but...... of course there wouldn't be a third quarter impact.......... Monday October 15, 6:20 pm Eastern Time Press Release SOURCE: BioReliance Corporation BioReliance Expects Third Quarter Results Substantially Higher Than Prior Guidance ROCKVILLE, Md., Oct. 15 /PRNewswire/ -- BioReliance Corporation (Nasdaq: BREL - news) stated that it expects earnings per share for its third quarter ended September 30, 2001 to be in a range of $0.24 to $0.26 compared to the $0.08 to $0.12 per share guidance provided in July, 2001. BioReliance plans to release comprehensive September quarter earnings information and updated guidance after the close of the market on October 24, 2001. It will hold an investor conference call to discuss the results of the third quarter at 10:00 am on Thursday, October 25, 2001. Listeners can participate by calling (303) 224-6997 or by logging onto the Website www.streetevents.com . Capers McDonald, President and CEO said, ``Every major segment of our business has contributed to the improvement in our anticipated results. We have been able to manage significant increases in revenue with a relatively constant cost base across all our business and geographic segments. We are gratified by the wide-spread confidence in us displayed by our customers.'' He continued, ``These results are being achieved without exceptional performance from any individual contract or from our start-up manufacturing facility. While the results from that operation have improved, and we expect them to continue to improve, our performance in the third quarter is due more to contributions from our testing and development business units, both in the United States and in Europe.'' McDonald concluded, ``There has been substantial press coverage of the opportunities that may accrue to certain companies, including BioReliance, as a result of the United States and worldwide responses to the tragic events of September 11, 2001. Although we must continue to maintain the degree of confidentiality required by all our clients, we can note that the results for the third quarter will not reflect a benefit from any business that eventually may develop in consequence of these events. We caution that it is early to determine what economic result, if any, may occur as we strive to serve the United States and its allies in these challenging times.'' (snip)